Lewy body dementia

Marion Delenclos, Simon Moussaud, Pamela J McLean

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lewy body dementia (LBD) is a term used to encompass both Parkinson's disease dementia and dementia with Lewy body disorders. They are the second most common type of dementia after Alzheimer's disease but are yet often misdiagnosed. Indeed, LBD appears to fall somewhere in the middle of a disease spectrum ranging from Alzheimer's to Parkinson's disease. LBD is characterized by manifestations of neuropsychiatric symptoms with motor impairment, and both disorders can be distinguished by the temporal manifestations of motor symptoms. The pathological hallmark of LBD is the presence of Lewy bodies with aggregated alpha-synuclein being a main component. To date, no cures are available for LBD. Consequently identifying and dissecting disease-modifying pathway for LBD is a priority for the discovery of neuroprotective therapeutics. Herein, we review promising targets and new innovative approaches. In this regard, strategies targeting the clearance of α-synuclein and prevention of its propagation will be discussed.

Original languageEnglish (US)
Title of host publicationDisease-Modifying Targets in Neurodegenerative Disorders
Subtitle of host publicationPaving the Way for Disease-Modifying Therapies
PublisherElsevier
Pages175-198
Number of pages24
ISBN (Electronic)9780128052662
ISBN (Print)9780128051207
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Lewy Body Disease
Parkinson Disease
Dementia
Synucleins
Lewy Bodies
alpha-Synuclein
Diagnostic Errors
Alzheimer Disease

Keywords

  • Alzheimer's disease
  • Dementia
  • Lewy bodies
  • Parkinson's disease
  • Parkinsonism
  • Propagation
  • Therapeutics
  • α-synuclein

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Delenclos, M., Moussaud, S., & McLean, P. J. (2017). Lewy body dementia. In Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies (pp. 175-198). Elsevier. https://doi.org/10.1016/B978-0-12-805120-7.00008-7

Lewy body dementia. / Delenclos, Marion; Moussaud, Simon; McLean, Pamela J.

Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies. Elsevier, 2017. p. 175-198.

Research output: Chapter in Book/Report/Conference proceedingChapter

Delenclos, M, Moussaud, S & McLean, PJ 2017, Lewy body dementia. in Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies. Elsevier, pp. 175-198. https://doi.org/10.1016/B978-0-12-805120-7.00008-7
Delenclos M, Moussaud S, McLean PJ. Lewy body dementia. In Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies. Elsevier. 2017. p. 175-198 https://doi.org/10.1016/B978-0-12-805120-7.00008-7
Delenclos, Marion ; Moussaud, Simon ; McLean, Pamela J. / Lewy body dementia. Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies. Elsevier, 2017. pp. 175-198
@inbook{a27c579ad8a247db8ee328fa150208d5,
title = "Lewy body dementia",
abstract = "Lewy body dementia (LBD) is a term used to encompass both Parkinson's disease dementia and dementia with Lewy body disorders. They are the second most common type of dementia after Alzheimer's disease but are yet often misdiagnosed. Indeed, LBD appears to fall somewhere in the middle of a disease spectrum ranging from Alzheimer's to Parkinson's disease. LBD is characterized by manifestations of neuropsychiatric symptoms with motor impairment, and both disorders can be distinguished by the temporal manifestations of motor symptoms. The pathological hallmark of LBD is the presence of Lewy bodies with aggregated alpha-synuclein being a main component. To date, no cures are available for LBD. Consequently identifying and dissecting disease-modifying pathway for LBD is a priority for the discovery of neuroprotective therapeutics. Herein, we review promising targets and new innovative approaches. In this regard, strategies targeting the clearance of α-synuclein and prevention of its propagation will be discussed.",
keywords = "Alzheimer's disease, Dementia, Lewy bodies, Parkinson's disease, Parkinsonism, Propagation, Therapeutics, α-synuclein",
author = "Marion Delenclos and Simon Moussaud and McLean, {Pamela J}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/B978-0-12-805120-7.00008-7",
language = "English (US)",
isbn = "9780128051207",
pages = "175--198",
booktitle = "Disease-Modifying Targets in Neurodegenerative Disorders",
publisher = "Elsevier",

}

TY - CHAP

T1 - Lewy body dementia

AU - Delenclos, Marion

AU - Moussaud, Simon

AU - McLean, Pamela J

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Lewy body dementia (LBD) is a term used to encompass both Parkinson's disease dementia and dementia with Lewy body disorders. They are the second most common type of dementia after Alzheimer's disease but are yet often misdiagnosed. Indeed, LBD appears to fall somewhere in the middle of a disease spectrum ranging from Alzheimer's to Parkinson's disease. LBD is characterized by manifestations of neuropsychiatric symptoms with motor impairment, and both disorders can be distinguished by the temporal manifestations of motor symptoms. The pathological hallmark of LBD is the presence of Lewy bodies with aggregated alpha-synuclein being a main component. To date, no cures are available for LBD. Consequently identifying and dissecting disease-modifying pathway for LBD is a priority for the discovery of neuroprotective therapeutics. Herein, we review promising targets and new innovative approaches. In this regard, strategies targeting the clearance of α-synuclein and prevention of its propagation will be discussed.

AB - Lewy body dementia (LBD) is a term used to encompass both Parkinson's disease dementia and dementia with Lewy body disorders. They are the second most common type of dementia after Alzheimer's disease but are yet often misdiagnosed. Indeed, LBD appears to fall somewhere in the middle of a disease spectrum ranging from Alzheimer's to Parkinson's disease. LBD is characterized by manifestations of neuropsychiatric symptoms with motor impairment, and both disorders can be distinguished by the temporal manifestations of motor symptoms. The pathological hallmark of LBD is the presence of Lewy bodies with aggregated alpha-synuclein being a main component. To date, no cures are available for LBD. Consequently identifying and dissecting disease-modifying pathway for LBD is a priority for the discovery of neuroprotective therapeutics. Herein, we review promising targets and new innovative approaches. In this regard, strategies targeting the clearance of α-synuclein and prevention of its propagation will be discussed.

KW - Alzheimer's disease

KW - Dementia

KW - Lewy bodies

KW - Parkinson's disease

KW - Parkinsonism

KW - Propagation

KW - Therapeutics

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=85032711338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032711338&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-805120-7.00008-7

DO - 10.1016/B978-0-12-805120-7.00008-7

M3 - Chapter

SN - 9780128051207

SP - 175

EP - 198

BT - Disease-Modifying Targets in Neurodegenerative Disorders

PB - Elsevier

ER -